Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 136

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 136
---
────────────────────────────────────────────────

  Compositions and methods for treating eating disorders: 1 pending application. The 20 year term for this family ends on March 20, 2045.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Psychoactive compounds, methods of their preparation and uses thereof in the treatment of mental disorders: 1 pending application  

  Psychedelic compounds, methods of their preparation and uses thereof: 1 pending application  

  5-methoxy-2-aminoindan in methods for treating metabolic syndrome. The 20 year term for this family ends on July 8, 2045.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

The Company intends to seek additional patents
for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build
its portfolio.

The Alcoholic Beverage Substitute patent family
discloses a large genus of compounds suitable for use in alcoholic beverage substitutes comprising a derivative of 2-aminoindan having
the characteristics of being intoxicating in a way like alcohol, being physiologically benign (non-harmful), and being devoid of interactions
with other drugs. A disclosed species of the genus is MEAI.

The Binge Behavior Regulators patent family discloses
compositions comprising a derivative of 2-aminoindan, as described herein, useful as binge regulators or binge mitigation agents that
impart a feeling of satisfaction, satiety or contentedness and thereby regulate (e. g., discourage) binge behavior such as binge drinking.

The Benzofurans as Fail Safes for MDMA Therapy
patent family discloses a method for treating subjects who are resistant to MDMA-assisted psychotherapy, or those for whom MDMA has become
ineffective, undesirable, or inappropriate.

The 2-FDCK for Treatment of Depression, Including
Treatment-Resistant Depression patent family is directed to methods of administering 2-fluorodeschloroketamine to treat depression, including
depression in patients who have developed resistance to previously used treatment therapies, such as ketamine.

Compositions comprising MEAI and n-acylethanolamines
and uses thereof patent family is part of our cooperation agreement with SciSparc. The invention disclosed therein is directed to the
compositions and methods for potentiating therapeutic effects and/or reducing side-effects of MEAI. The present invention provides pharmaceutical